A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
This research is looking into a new medicine called KK8123 for people aged 18 to 65 who have X-linked Hypophosphatemia (XLH). This is the very first time this medicine is being tested in humans. The main goal is to find out if KK8123 is safe, what the right dose might be, and how it behaves in the body. Researchers will also be checking if it helps improve the condition. The study involves different stages, including an initial health check, a period where participants receive the medicine, and an optional longer follow-up period. It's an important step in developing new treatments for XLH, aiming to understand the medicine better before it can be studied in larger groups.
A colpo d'occhio
Di cosa tratta questo studio?
This clinical trial is an important step in understanding a new medicine called KK8123, which is being developed for people with a condition called X-linked Hypophosphatemia (often shortened to XLH). XLH is a rare genetic disorder that affects how the body handles phosphate, a mineral vital for strong bones and teeth. People with XLH often have low levels of phosphate in their blood, which can lead to weakened bones, pain, and other health issues.
The study is called a 'first-in-human' study, which means it's the very first time this particular medicine is being given to people. Because of this, it's divided into two main parts (Phase 1 and Phase 2). In these early phases, the primary focus is not on whether the medicine cures XLH, but on making sure it's safe for people to take. Researchers will carefully check for any side effects and work out the best dose to give.
By taking part, individuals are helping doctors and scientists learn more about XLH and explore potential new treatments. The information gathered from this study will be crucial for deciding whether KK8123 can be tested in larger groups of people later on, with the hope that it might eventually become a new way to help manage XLH.
Punti chiave
- This is a 'first-in-human' study for a new XLH medicine, KK8123.
- The primary goals are to check the medicine's safety, side effects, and how it acts in the body.
- Participants must be adults (18-65) with XLH and good kidney function.
- The study involves a screening period, a treatment period (32-44 weeks), and an optional extension.
- Close medical monitoring will be provided throughout the study.
- You have the right to withdraw from the study at any time.
Chi può essere idoneo?
To be considered for this study, you need to be an adult between 18 and 65 years old. You must have a confirmed diagnosis of X-linked Hypophosphatemia (XLH) and blood tests showing low phosphate levels. Your kidney function also needs to be healthy enough to take part.
There are some other important requirements. You must weigh at least 6 stone 4 pounds (40 kg) and be able to give your informed consent. If you are female and could become pregnant, you'll need to have a negative pregnancy test and agree to use effective contraception during and for some time after the study. The same applies to male participants who could father a child. If you take pain medication, it needs to be at a stable dose. You also need to be willing to keep your diet and exercise routines consistent throughout the study.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Hai tra i 18 e i 65 anni?
- Do you have a diagnosis of X-linked Hypophosphatemia (XLH)?
- Are your blood phosphate levels currently low?
- Do you weigh at least 6 stone 4 pounds (40 kg)?
- Are you able to use contraception if you could become pregnant or father a child?
- Are you willing to stick to your usual diet and exercise routines during the study?
Cosa comporta la partecipazione?
If you decide to take part, the first step is a 'screening period' which can last up to 28 days. During this time, you'll have various checks and tests to make sure you meet all the requirements for the study. If you qualify, you'll enter the 'treatment period'. This part involves taking the study medicine, KK8123, and attending regular appointments so the research team can monitor your health, check for any side effects, and see how the medicine is working. This treatment and observation period will last between 32 and 44 weeks. After this, some participants might be offered the chance to continue in an 'extension period' for further monitoring if they wish. Throughout the study, you'll be giving blood samples and having other medical assessments.
Rischi e benefici potenziali
Luoghi (9)
- University of California - San FranciscoCodice postale verificatoSan Francisco, Stati Uniti· Reclutamento
- Yale Center for XLH/ Yale University School of MedicineCodice postale verificatoNew Haven, Stati Uniti· Reclutamento
- Indiana University School of Medicine University HospitalCodice postale verificatoIndianapolis, Stati Uniti· Reclutamento
- Mayo ClinicCodice postale verificatoRochester, Stati Uniti· Non ancora in fase di reclutamento
- Vanderbilt University Medical CenterCodice postale verificatoNashville, Stati Uniti· Reclutamento
- Hoptial BictreCodice postale verificatoLe Kremlin-Bicêtre, France· Reclutamento
- Institute of Osteology and Biomechanics (IOBM)Codice postale verificatoAmburgo, Germania· Reclutamento
- Universitaetsklinikum WurzburgCodice postale verificatoWürzburg, Germania· Reclutamento
- Hospital Universitario La PazCodice postale verificatoMadrid, Spagna· Reclutamento
Domande comuni
What is X-linked Hypophosphatemia (XLH)?
XLH is a rare inherited condition that causes low levels of phosphate in the blood, leading to problems like soft bones, pain, and dental issues.
What is the purpose of KK8123?
KK8123 is a new medicine being developed to potentially help manage XLH. This study is the first time it's being tested in people to check its safety and how it works.
Quanto dura lo studio?
The initial screening period can be up to 28 days. If you qualify, the main treatment part of the study will last between 32 and 44 weeks, with an option to continue in an extension period.
Will I receive KK8123 if I join?
Yes, if you meet the study requirements and are enrolled, you will receive the study medicine, KK8123, as this is a dose-escalation study where participants receive the active drug.
What happens if I change my mind during the study?
You are free to leave the study at any time, for any reason. Your decision will not affect your ongoing medical care.
Come saperne di più
Kyowa Kirin
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Interessato a partecipare?
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.